Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib starting dose comparison with everolimus in previously VEGF-treated renal cell carcinoma
2016-002778-11Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib and everolimus in renal cell carcinoma (RCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Objective response rate at Week 24. Started May 2017; status: completed.
02
Drugs
lenvatinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-002778-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002778-11.